1. Home
  2. SCYX vs CRWS Comparison

SCYX vs CRWS Comparison

Compare SCYX & CRWS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SCYX
  • CRWS
  • Stock Information
  • Founded
  • SCYX 1999
  • CRWS 1957
  • Country
  • SCYX United States
  • CRWS United States
  • Employees
  • SCYX N/A
  • CRWS N/A
  • Industry
  • SCYX Biotechnology: Pharmaceutical Preparations
  • CRWS Textiles
  • Sector
  • SCYX Health Care
  • CRWS Consumer Discretionary
  • Exchange
  • SCYX Nasdaq
  • CRWS Nasdaq
  • Market Cap
  • SCYX 32.3M
  • CRWS 30.5M
  • IPO Year
  • SCYX 2014
  • CRWS N/A
  • Fundamental
  • Price
  • SCYX $0.79
  • CRWS $2.91
  • Analyst Decision
  • SCYX
  • CRWS
  • Analyst Count
  • SCYX 0
  • CRWS 0
  • Target Price
  • SCYX N/A
  • CRWS N/A
  • AVG Volume (30 Days)
  • SCYX 574.3K
  • CRWS 34.0K
  • Earning Date
  • SCYX 11-05-2025
  • CRWS 11-11-2025
  • Dividend Yield
  • SCYX N/A
  • CRWS 10.92%
  • EPS Growth
  • SCYX N/A
  • CRWS N/A
  • EPS
  • SCYX N/A
  • CRWS N/A
  • Revenue
  • SCYX $3,257,000.00
  • CRWS $86,516,000.00
  • Revenue This Year
  • SCYX $422.61
  • CRWS N/A
  • Revenue Next Year
  • SCYX $240.56
  • CRWS N/A
  • P/E Ratio
  • SCYX N/A
  • CRWS N/A
  • Revenue Growth
  • SCYX N/A
  • CRWS N/A
  • 52 Week Low
  • SCYX $0.66
  • CRWS $2.76
  • 52 Week High
  • SCYX $1.62
  • CRWS $4.96
  • Technical
  • Relative Strength Index (RSI)
  • SCYX 36.53
  • CRWS 47.13
  • Support Level
  • SCYX $0.74
  • CRWS $2.92
  • Resistance Level
  • SCYX $1.14
  • CRWS $2.99
  • Average True Range (ATR)
  • SCYX 0.07
  • CRWS 0.06
  • MACD
  • SCYX -0.04
  • CRWS 0.00
  • Stochastic Oscillator
  • SCYX 11.22
  • CRWS 58.33

About SCYX SCYNEXIS Inc.

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

About CRWS Crown Crafts Inc

Crown Crafts Inc operates in the infant and toddler products segment of the consumer products industry through its wholly-owned subsidiaries. The infant and toddler products segment consists of infant and toddler bedding, bibs, soft bath products, disposable products, and accessories. The company serves a diverse range of customers including mass merchants, mid-tier retailers, juvenile specialty stores, value channel stores, grocery and drug stores, restaurants, internet accounts, wholesale clubs, and internet-based retailers. The company's brands include NoJo, Neat Solutions, Sassy, and Carousel. Its products are marketed under a variety of company-owned trademarks, under trademarks licensed from others, and as private-label goods.

Share on Social Networks: